EGFR and lung cancer: In recent years, various biological markers, such as the nucleotide excision repair pathway, cell-cycle regulators, β-tubulin class III, epidermal growth factor receptor mutations, and gene expression profiling, have been explored to predict the efficacy of traditional chemotherapies in patients with lung cancer [37, 38].